Patents by Inventor John A. Lewicki

John A. Lewicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6903096
    Abstract: The invention is directed to methods to inhibit TGF-? and/or p38-? kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar? is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: June 7, 2005
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6897030
    Abstract: Immunoassays and antibodies useful in conducting them for human and canine brain natriuretic peptide are described.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: May 24, 2005
    Assignee: Scios, Inc.
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Publication number: 20050003510
    Abstract: Methods and compositions for targeting heterologous polypeptides to bacterial cell walls are provided.
    Type: Application
    Filed: January 28, 2004
    Publication date: January 6, 2005
    Applicant: OSEL, INC.
    Inventors: Chia-Hwa Chang, Xiaowen Liu, John Lewicki, Qiang Xu
  • Patent number: 6709855
    Abstract: The present invention relates to methods and compositions for the detection, diagnosis, prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and related disorders. The present invention also relates to compositions and methods useful in the diagnosis, prevention and therapeutic treatment of a disease, specifically cardiac, kidney or inflammatory disease. Specifically, methods and compositions are provided for the diagnostic evaluation and prognosis of conditions involving a disease, specifically cardiac, kidney or inflammatory disease, for the identification of subjects exhibiting a predisposition to such conditions, for modulating the effect of these differentially expressed genes, for monitoring patients undergoing clinical evaluation for the prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and its disorders, and for monitoring the efficacy of compounds used in clinical trials.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: March 23, 2004
    Assignee: Scios, Inc.
    Inventors: Lawrence W. Stanton, R. Tyler White, Deborah L. Damm, John A. Lewicki, Alison Joly, George F. Schreiner
  • Publication number: 20040002458
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
    Type: Application
    Filed: March 27, 2003
    Publication date: January 1, 2004
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Publication number: 20030228297
    Abstract: The present invention relates to Lactobacillus species recombinantly altered to express a biologically active protein. The invention also related to methods of providing the bacteria to the vagina.
    Type: Application
    Filed: March 6, 2003
    Publication date: December 11, 2003
    Applicant: Osel, Inc.
    Inventors: Chia-Hwa Chang, David A. Simpson, Theresa Li-Yun Chang, Qiang Xu, John A. Lewicki
  • Patent number: 6589954
    Abstract: Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful in treating cardiac conditions associated with heart failure and in treating conditions characterized by proinflammation.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: July 8, 2003
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, David Y. Liu, George F. Schreiner, John A. Lewicki, John J. Perumattam
  • Patent number: 6586396
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: July 1, 2003
    Assignee: Scios, Inc.
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Publication number: 20030109430
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
    Type: Application
    Filed: July 9, 2001
    Publication date: June 12, 2003
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Publication number: 20030073699
    Abstract: The invention is directed to compounds of the formula 1
    Type: Application
    Filed: February 13, 2002
    Publication date: April 17, 2003
    Inventors: Babu J. Mavunkel, David Y. Liu, George F. Schreiner, John A. Lewicki, John J. Perumattam
  • Publication number: 20030069248
    Abstract: The invention is directed to methods to inhibit TGF-&bgr;and/or p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: October 2, 2001
    Publication date: April 10, 2003
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6541477
    Abstract: The invention is directed to methods for treating conditions mediated by by P38&agr; kinase using compounds of the formula wherein Ar1 and Ph are limited to specific embodiments or wherein the compound of formula (3) is a compound set forth in FIGS. 1A-1T.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: April 1, 2003
    Assignee: Scios, Inc.
    Inventors: R. Richard Goehring, Babu J. Mavunkel, David Y. Liu, George F. Schreiner, Gregory Leudtke, John A. Lewicki
  • Patent number: 6476031
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: November 5, 2002
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Publication number: 20020161010
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula 1
    Type: Application
    Filed: October 5, 2001
    Publication date: October 31, 2002
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6448257
    Abstract: Compounds of the formula: wherein the dotted line represents an optional bond; and the pharmaceutically acceptable salts thereof, wherein X1 is an alkyl bridge optionally containing an O, S, or N heteroatom that forms an aliphatic 5-7 membered ring and is optionally substituted by one or more of halo, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by one or more CN or═O, or by one or more aliphatic or aromatic 5- or 6-membered rings optionally containing 1-2 heteroatoms; R1 is  wherein X2 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two Y taken together may form an alkylene (2-3C) bridge; n is 0-4; Z1 is CH or N; X3 is CH or CHR where R is H or alkyl (1-6C), or an isostere thereof; and Ar, R2 and R3 are as defined in the specification. These compounds are selective inhibitors of p38&agr; kinase.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: September 10, 2002
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, David Y. Liu, George F. Schreiner, John A. Lewicki
  • Publication number: 20020115671
    Abstract: The invention is directed to prepare medicaments for treatment of and to methods to treat conditions mediated by kinase using compounds of the formula 1
    Type: Application
    Filed: February 28, 2001
    Publication date: August 22, 2002
    Inventors: R. Richard Goehring, Babu J. Mavunkel, David Y. Liu, George F. Schreiner, Gregory Leudtke, John A. Lewicki
  • Patent number: 6410540
    Abstract: The invention is directed to methods to treat conditions mediated by p38-&agr;kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein Z is N or CR1, R1 is a noninterfering substituent, each of X1 and X2 is a linker, Ar1 and Ar2 are identical or different, and represent optionally substituted C1-C20 hydrocarbyl residues wherein at least one of Ar1 and Ar2 is an optionally substituted aryl group, with the proviso that when X2 is CH2 or an isostere thereof, X1 is CO or an isostere thereof, and Ar2 is optionally substituted phenyl, Ar1 is other than an optionally substituted indolyl, benzimidazolyl or benzotriazolyl substituent, and wherein said optionally substituted phenyl is not an optionally substituted indolyl, benzimidazolyl, or benzotriazolyl, Y is a noninterfering substituent, wherein n is an integer from 0-4, and wherein m is an integer from 0-4 and 1 is an integer from 0-3.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: June 25, 2002
    Assignee: Scios, Inc.
    Inventors: R. Richard Goehring, Gregory R. Luedtke, Babu J. Mavunkel, Sarvajit Chakravarty, Sundeep Dugar, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6340685
    Abstract: A compound of the formula: and the pharmaceutically acceptable salts thereof, wherein each of Z1 and Z2 is independently CR4 or N; where each R4 is independently H or is alkyl (1-6C) optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by CN or ═O, or by an aliphatic or aromatic 5 or 6 membered ring optionally containing 1-2 N heteroatoms; or two R4 taken together form a bridge optionally containing a heteroatom; R1 is  wherein X1 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two 6 taken together may form an alkyene (2-3C) bridge; n is 0 or 2; Z3 is CH or N; X2 is CH, CH2 or an isostere thereof; and Ar consists of one or two phenyl moieties directly coupled to X2 optionally substituted by halo, nitro, alkyl (1-
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: January 22, 2002
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, John A. Lewicki, David Y. Liu, George F. Schreiner, John J. Perumattam
  • Patent number: 6277989
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: August 21, 2001
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6184226
    Abstract: The invention describes compounds of the formula and the pharmaceutically acceptable salts thereof and the pharmaceutically acceptable salts thereof wherein each R2 is independently a noninterfering substituent; m is an integer of 0-4; Z is CH or N; R1 is H, alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR2, SR, —OOCR, —NROCR, RCO, —COOR, —CONR2, —SO2NR2, CN, CF3, and NO2, wherein each R is independently H or lower alkyl (1-4C); n is 0, 1 or 2; Ar is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR2, SR, —OOCR, —NROCR, RCO, —COOR, —CONR2, SO2NR2, CN, CF3, and NO2, wherein each R is independently H or lower alkyl (1-4C); and R3 is a branched or cyclic alkyl group (5-7C) or is phenyl optionally substituted with 1-2 substi
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: February 6, 2001
    Assignee: Scios Inc.
    Inventors: Sarvajit Chakravarty, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki